Nyxoah S.A. (NASDAQ:NYXH) Short Interest Down 17.4% in October

Nyxoah S.A. (NASDAQ:NYXH) was the target of a large drop in short interest in October. As of October 31st, there was short interest totalling 58,800 shares, a drop of 17.4% from the October 15th total of 71,200 shares. Approximately 0.4% of the company’s stock are short sold. Based on an average trading volume of 63,200 shares, the short-interest ratio is currently 0.9 days.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Oppenheimer reduced their target price on Nyxoah from $15.00 to $13.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. HC Wainwright decreased their price objective on Nyxoah from $18.00 to $17.00 and set a “buy” rating for the company in a report on Friday, October 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 target price on shares of Nyxoah in a report on Tuesday, November 5th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $17.00.

Nyxoah Price Performance

Shares of NYXH traded down $0.21 during trading hours on Friday, reaching $8.22. 18,951 shares of the company traded hands, compared to its average volume of 49,495. The stock has a market capitalization of $205.01 million, a PE ratio of -4.40 and a beta of 1.45. The stock has a fifty day simple moving average of $9.06 and a 200 day simple moving average of $8.73. Nyxoah has a fifty-two week low of $4.00 and a fifty-two week high of $20.00. The company has a quick ratio of 4.95, a current ratio of 5.28 and a debt-to-equity ratio of 0.21.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Kovack Advisors Inc. acquired a new position in Nyxoah during the third quarter valued at approximately $96,000. Ikarian Capital LLC purchased a new stake in Nyxoah during the 1st quarter worth $684,000. CVI Holdings LLC purchased a new stake in shares of Nyxoah during the second quarter worth about $1,292,000. Finally, Iron Triangle Partners LP acquired a new position in shares of Nyxoah in the first quarter worth about $3,413,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.